Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease. Our other products seek to augment longevity by targeting organ and tissue repair and functional regeneration. With this approach, our ambition is to augment human immunity and longevity, and to improve the human health span.

Backed by 100+ years of combined experience, our seasoned team of biopharmaceutical executives, scientists and clinicians has been integral to the success of numerous programs across discovery research, clinical development and commercialization in cancer immunotherapies and cell therapeutics. Everyone at Celularity is passionate about developing innovative treatment options that will make a meaningful difference in patients’ lives.